BayVax Biotech
Developer of AI-driven computational immunology platforms for design and validation of antigens and T-cell receptors, focused on personalized neoantigen vaccines and broad‑spectrum vaccine candidates. Advances computational models into preclinical and clinical development through collaborations, licensing, and investigator-initiated trials.
Industries
Nr. of Employees
small (1-50)
Products
BXP-001 (Neoantigen cancer vaccine candidate)
Peptide-based neoantigen vaccine candidate advanced to investigator-initiated clinical evaluation for solid tumors.
BVX-COV (Pan-coronavirus vaccine candidate)
Viral-vector vaccine candidate designed for broad coronavirus coverage, validated in-silico and progressed to preclinical evaluation.
BVX-AGE (Senolytic / anti‑aging vaccine candidate)
Protein-based vaccine candidate designed with computational antigen design methods for age-related targets; currently in early development.
BVX-AID (Autoimmune disease vaccine candidate)
Peptide-based vaccine candidate designed for autoimmune disease applications using in-silico design workflows.
BXP-001 (Neoantigen cancer vaccine candidate)
Peptide-based neoantigen vaccine candidate advanced to investigator-initiated clinical evaluation for solid tumors.
BVX-COV (Pan-coronavirus vaccine candidate)
Viral-vector vaccine candidate designed for broad coronavirus coverage, validated in-silico and progressed to preclinical evaluation.
BVX-AGE (Senolytic / anti‑aging vaccine candidate)
Protein-based vaccine candidate designed with computational antigen design methods for age-related targets; currently in early development.
BVX-AID (Autoimmune disease vaccine candidate)
Peptide-based vaccine candidate designed for autoimmune disease applications using in-silico design workflows.
Services
Provision of validated digital pipelines for antigen design and immunogenicity prediction via licensing or co-development agreements.
In-silico design services for personalized neoantigen vaccines and broad‑spectrum antigen candidates using generative and predictive models.
Provision of validated digital pipelines for antigen design and immunogenicity prediction via licensing or co-development agreements.
In-silico design services for personalized neoantigen vaccines and broad‑spectrum antigen candidates using generative and predictive models.
Expertise Areas
- Computational immunology
- AI-driven antigen and TCR design
- Personalized neoantigen vaccine development
- Preclinical toxicology and IND-enabling studies
Key Technologies
- Deep learning for immunology
- Generative sequence models (TCR/antigen design)
- Peptide-MHC-TCR interaction modeling
- In-silico HLA genotyping
News & Updates
Regulatory pathway opened for neoantigen vaccines, initiating Investigational New Drug application activities.
IIT at The University of Hong Kong-Shenzhen Hospital started and reported promising progression-free survival extension.
Results published for a tender for IND-enabling preclinical toxicology (TOX-2025-001) including timeline and awarded vendor.
Preprint describing a generative model for TCR variable regions with applications to cellular therapy.
Phase II randomized clinical trial report on individualized neoantigen peptide vaccine combined with radiotherapy in advanced solid tumors.
Study on virological features and immune evasion relevant to vaccine development.
Regulatory pathway opened for neoantigen vaccines, initiating Investigational New Drug application activities.
IIT at The University of Hong Kong-Shenzhen Hospital started and reported promising progression-free survival extension.
Results published for a tender for IND-enabling preclinical toxicology (TOX-2025-001) including timeline and awarded vendor.
Preprint describing a generative model for TCR variable regions with applications to cellular therapy.
Phase II randomized clinical trial report on individualized neoantigen peptide vaccine combined with radiotherapy in advanced solid tumors.
Study on virological features and immune evasion relevant to vaccine development.